Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
Bridget A Graney, Joyce S Lee Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Abstract: Patients with idiopathic pulmonary fibrosis, an incurable, progressive fibrotic interstitial lung disease, suffer an impaired quality of...
Main Authors: | Graney BA, Lee JS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Patient Related Outcome Measures |
Subjects: | |
Online Access: | https://www.dovepress.com/impact-of-novel-antifibrotic-therapy-on-patient-outcomes-in-idiopathic-peer-reviewed-article-PROM |
Similar Items
-
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01) -
Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01) -
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01) -
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01) -
Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01)